Want to see NASC full AI Analyst Report?
NASC Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.04
Previous CloseN/A
Volume1.00
Average Volume (3M)35.25K
Market Cap
$2.13M
Enterprise Value$9.54M
Total Cash (Recent Filing)$7.88K
Total Debt (Recent Filing)$9.01M
Price to Earnings (P/E)―
Beta-0.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding142,229,160
10 Day Avg. Volume42,355
30 Day Avg. Volume35,253
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap4.47
Enterprise Value/Revenue9.23
Enterprise Value/Gross Profit-6.00
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Industry TrendsFavorable industry trends, such as increased legalization and consumer interest, provide a supportive backdrop for Can B's growth and market penetration efforts.
Product DiversificationA broad product portfolio allows Can B to capture diverse consumer preferences, reducing dependency on a single product line and enhancing resilience against market fluctuations.
Market ExpansionStrategic partnerships enhance Can B's market presence, enabling broader distribution and access to new customer segments, supporting long-term revenue growth.
Bears Say
Revenue DeclineDeclining revenue trends indicate potential market share loss and operational inefficiencies, challenging Can B's growth prospects and competitive positioning.
Profitability ChallengesOngoing profitability issues hinder Can B's ability to generate sustainable earnings, affecting long-term viability and shareholder value creation.
Financial HealthNegative equity and insolvency risks undermine Can B's financial stability, limiting its ability to invest in growth opportunities and weather economic downturns.
NASC FAQ
What was Nascent Pharma Holdings’s price range in the past 12 months?
Nascent Pharma Holdings lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
What is Nascent Pharma Holdings’s market cap?
Nascent Pharma Holdings’s market cap is $2.13M.
When is Nascent Pharma Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nascent Pharma Holdings’s earnings last quarter?
Nascent Pharma Holdings released its earnings results on May 30, 2023. The company reported -$0.355 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.355.
Is Nascent Pharma Holdings overvalued?
According to Wall Street analysts Nascent Pharma Holdings’s price is currently Overvalued.
Does Nascent Pharma Holdings pay dividends?
Nascent Pharma Holdings does not currently pay dividends.
What is Nascent Pharma Holdings’s EPS estimate?
Nascent Pharma Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nascent Pharma Holdings have?
Nascent Pharma Holdings has 142,229,160 shares outstanding.
What happened to Nascent Pharma Holdings’s price movement after its last earnings report?
Nascent Pharma Holdings reported an EPS of -$0.355 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.526%.
Which hedge fund is a major shareholder of Nascent Pharma Holdings?
Currently, no hedge funds are holding shares in NASC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nascent Pharma Holdings
Nascent Pharma Holdings, Inc. is primarily engaged in both protecting and bringing to market intellectual property pertaining to cannabis. Beyond this, the company also manufactures superfood beverage mixes, which are marketed under its "Longevity" brand. Established in 2005 and headquartered in Hicksville, New York, the firm previously operated as Can B Corp. and is slated to officially adopt the Nascent Pharma Holdings, Inc. name in September 2025.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―